Search - tctmd.com

Displaying 21 - 40 of 103

Sort: Relevancy | Date

Presentation TVT 2019

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A Two-Year Analysis From the SURTAVI Trial

Presenter: Mark Tuttle

June 15, 2019

Presentation TVT 2019

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

Presenter: Mark Tuttle

June 13, 2019

News Daily News

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

Todd Neale

October 22, 2018

Presentation TCT 2018

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

Presenter: Horst Sievert, Brian K. Whisenant, Jeffrey J. Popma

September 23, 2018

News Conference News PCR London Valves 2018

Ten-Year Trends in the UK Show TAVR Rates Rising but SAVR Holding Steady

Shelley Wood

September 11, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

Presentation TCT 2017

SURTAVI Trial Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, E. Murat Tuzcu

November 01, 2017

Presentation TCT 2017

SURTAVI: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Presenter: Jean-Claude Laborde, Eric Van Belle, Lars Sondergaard

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Advertisement

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A Two-Year Analysis From the SURTAVI Trial

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

SURTAVI Stroke Analysis Published, Confirms Less Early Stroke With TAVR

SURTAVI: Two-Year Complete Results From a Randomized Trial of a Self-Expanding Transcatheter Heart Valve vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk

Ten-Year Trends in the UK Show TAVR Rates Rising but SAVR Holding Steady

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

SURTAVI Trial Critique and Unanswered Questions

SURTAVI: Topline Findings and Practice Implications

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

TCTMD’s Top 10 Most Popular Stories for July 2017

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content